We provide you with 20 years of free, institutional-grade data for GILD stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GILD. Explore the full financial landscape of GILD stock.
Reported Date | CIK | Ticker | Type | |
---|---|---|---|---|
2025-08-07 | 882095 | GILD | 10-Q | Url |
2025-05-07 | 882095 | GILD | 10-Q | Url |
2025-02-28 | 882095 | GILD | 10-K | Url |
2024-11-12 | 882095 | GILD | 10-Q | Url |
2024-08-08 | 882095 | GILD | 10-Q | Url |
2024-05-08 | 882095 | GILD | 10-Q | Url |
2024-02-23 | 882095 | GILD | 10-K | Url |
2023-11-07 | 882095 | GILD | 10-Q | Url |
2023-08-04 | 882095 | GILD | 10-Q | Url |
2023-05-03 | 882095 | GILD | 10-Q | Url |
2023-02-22 | 882095 | GILD | 10-K | Url |
2022-11-02 | 882095 | GILD | 10-Q | Url |
2022-08-08 | 882095 | GILD | 10-Q | Url |
2022-05-04 | 882095 | GILD | 10-Q | Url |
2022-02-23 | 882095 | GILD | 10-K | Url |
2021-11-03 | 882095 | GILD | 10-Q | Url |
2021-08-05 | 882095 | GILD | 10-Q | Url |
2021-05-06 | 882095 | GILD | 10-Q | Url |
2021-02-25 | 882095 | GILD | 10-K | Url |
2020-11-04 | 882095 | GILD | 10-Q | Url |
2020-08-06 | 882095 | GILD | 10-Q | Url |
2020-05-06 | 882095 | GILD | 10-Q | Url |
2020-02-25 | 882095 | GILD | 10-K | Url |
2019-11-05 | 882095 | GILD | 10-Q | Url |
2019-08-06 | 882095 | GILD | 10-Q | Url |
2019-05-08 | 882095 | GILD | 10-Q | Url |
2019-02-26 | 882095 | GILD | 10-K | Url |
2018-11-06 | 882095 | GILD | 10-Q | Url |
2018-08-06 | 882095 | GILD | 10-Q | Url |
2018-05-09 | 882095 | GILD | 10-Q | Url |
2018-02-27 | 882095 | GILD | 10-K | Url |
2017-11-07 | 882095 | GILD | 10-Q | Url |
2017-08-07 | 882095 | GILD | 10-Q | Url |
2017-05-10 | 882095 | GILD | 10-Q | Url |
2017-02-27 | 882095 | GILD | 10-K | Url |
2016-11-07 | 882095 | GILD | 10-Q | Url |
2016-08-05 | 882095 | GILD | 10-Q | Url |
2016-05-06 | 882095 | GILD | 10-Q | Url |
2016-02-24 | 882095 | GILD | 10-K | Url |
2015-11-04 | 882095 | GILD | 10-Q | Url |
2015-08-05 | 882095 | GILD | 10-Q | Url |
2015-05-08 | 882095 | GILD | 10-Q | Url |
2015-02-25 | 882095 | GILD | 10-K | Url |
2014-11-05 | 882095 | GILD | 10-Q | Url |
2014-08-04 | 882095 | GILD | 10-Q | Url |
2014-05-07 | 882095 | GILD | 10-Q | Url |
2014-02-25 | 882095 | GILD | 10-K | Url |
2013-10-31 | 882095 | GILD | 10-Q | Url |
2013-08-01 | 882095 | GILD | 10-Q | Url |
2013-05-08 | 882095 | GILD | 10-Q | Url |
2013-02-27 | 882095 | GILD | 10-K | Url |
2012-11-06 | 882095 | GILD | 10-Q | Url |
2012-08-01 | 882095 | GILD | 10-Q | Url |
2012-05-04 | 882095 | GILD | 10-Q | Url |
2012-02-23 | 882095 | GILD | 10-K | Url |
2011-11-04 | 882095 | GILD | 10-Q | Url |
2011-08-05 | 882095 | GILD | 10-Q | Url |
2011-05-09 | 882095 | GILD | 10-Q | Url |
2011-02-28 | 882095 | GILD | 10-K | Url |
2010-11-08 | 882095 | GILD | 10-Q | Url |
2010-08-09 | 882095 | GILD | 10-Q | Url |
2010-05-10 | 882095 | GILD | 10-Q | Url |
2010-03-01 | 882095 | GILD | 10-K | Url |
2009-11-05 | 882095 | GILD | 10-Q | Url |
2009-08-05 | 882095 | GILD | 10-Q | Url |
2009-05-07 | 882095 | GILD | 10-Q | Url |
2009-02-27 | 882095 | GILD | 10-K | Url |
2008-10-31 | 882095 | GILD | 10-Q | Url |
2008-08-11 | 882095 | GILD | 10-Q | Url |
2008-05-02 | 882095 | GILD | 10-Q | Url |
2008-02-27 | 882095 | GILD | 10-K | Url |
Gilead Sciences, Inc(NASDAQ:GILD)

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, ...
Website: http://www.gilead.com
Founded: 1987
Full Time Employees: 11,800
Sector: Healthcare
Industry: Drug Manufacturers-General
The information provided in this report about GILD stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.